DAJY(SZ:002030)2023-11-15 23:38Group 1: Company Performance and Pricing Strategy - The initial price of the company's COVID-19 products was over 100 yuan, which has decreased to over 3 yuan after several rounds of large-scale procurement [1] - The company has maintained good financial performance despite the declining product prices [1][2] - The reduction in production costs is attributed to large-scale production and technological improvements, allowing for better cost control [2] Group 2: Market Share and Product Development - The company has achieved a market share of up to 60% for some products, maintaining a high market presence since its listing in 2004 [2] - The product range includes respiratory pathogens, influenza pathogens, gastrointestinal and foodborne pathogens, reproductive health, personalized tumor testing, and genetic testing [2] Group 3: Financial Outlook and Strategic Plans - The decline in profit during the third quarter was primarily due to product price adjustments and operational restructuring [2] - The company is cautiously optimistic about future investments and acquisitions, focusing on market trends and technological advancements [2] - There is a growing trend in the molecular market, with potential for molecular products to gradually replace immunological or biochemical products [2][3]